PRESSR: Novo Nordisk partners with Saudi Heart Association to improve cardiovascular health in Saudi Arabia

Riyadh, Saudi Arabia, - Novo Nordisk, a leading global healthcare company, is excited to announce a new Memorandum of Understanding with the Saudi Heart Association (SHA), aimed at improving cardiovascular care throughout Saudi Arabia. This strategic partnership will engage clinicians in a series of educational and research initiatives designed to provide optimal, multidisciplinary care for patients across the Kingdom.

The collaboration seeks to enhance patient outcomes nationwide by equipping healthcare professionals with vital knowledge and resources. This effort aligns with the objectives of Saudi Vision 2030, which aims to address the clinical and economic challenges posed by cardiovascular disease.

Cardiovascular diseases present a significant public health challenge in Saudi Arabia, with rising rates of related major risk factors, including obesity, diabetes, and inflammation. Besides traditional risk factors, systemic low-grade inflammation is nowadays recognized as a driving force of atherosclerotic disease progression and plaque destabilization. In 2016, approximately 201,300 Saudi nationals were affected by cardiovascular diseases, accounting for over 45% of fatalities in the country. This partnership is dedicated to tackling these pressing issues by fostering effective management strategies and enhancing clinical practices.

Novo Nordisk and SHA are committed to establishing a comprehensive framework for early intervention, significantly improving the quality of care provided to patients. The partnership will leverage diverse communication channels to reach healthcare providers, delivering thorough education on the latest advancements in cardiovascular care.

"At Novo Nordisk, we understand the critical importance of collaboration in advancing cardio care," said Melvin D’Souza, General Manager at Novo Nordisk Saudi Arabia. "Our partnership with the Saudi Heart Association marks a proactive step toward enhancing cardiovascular health practices and ultimately improving patient outcomes across the Kingdom."

"We are thrilled about this collaboration with Novo Nordisk and its potential impact," stated Dr. Waleed AlHabeeb, President of the Saudi Heart Association. "By working together, we can empower healthcare providers with the essential knowledge and skills to effectively manage cardiovascular patients, contributing to a healthier future for our communities."

About Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

About Saudi Heart Association

Saudi Heart Association (SHA) is a professional organization dedicated to advancing the field of cardiology in Saudi Arabia. Founded in 1987, it serves as a scientific reference for local bodies and works to disseminate knowledge and best practices in cardiovascular health. SHA is involved in various activities, including research, training, and public awareness campaigns, and hosts an annual conference.bb

Contacts for further information

Media:

Julie Andersen

Public Affairs Specialist

LJRT@novonordisk.com

Islam Tawfik 

Sr. Medical Manager

IZQT@novonordisk.com

References

• Tash, Adel Abdulkader and Al-Bawardy, Rasha Fahad (2023) "Cardiovascular Disease in Saudi Arabia: facts and the way forward," Journal of the Saudi Heart Association: Vol. 35: Iss. 2, Article 6. Available at: https://doi.org/10.37616/2212-5043.1336

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.